Year: 2023
Type: article
Study design: Clinical Trial
Abstract: BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels due to profoundly defective LDL receptor (LDLR) function. Given that severely elevated LDL-C starts in utero, atherosclerosis often presents during childhood or adolescence, creating a largely unmet need for aggressive LDLR-independent lipid-lowering therapies in young patients with HoFH. Here we present the first evaluation of the efficacy and safety of evinacumab, a novel LDLR-independent lipid-lowering therapy, in pediatric patients with HoFH from parts A and B of a 3-part study. METHODS: The phase 3, part B, open-label study treated 14 patients 5 to 11 years of age with genetically proven HoFH (true homozygotes and compound heterozygotes) with LDL-C >130 mg/dL, despite optimized lipid-lowering therapy (including LDLR-independent apheresis and lomitapide), with intravenous evinacumab 15 mg/kg every 4 weeks. RESULTS: Evinacumab treatment rapidly and durably (through week 24) decreased LDL-C with profound reduction in the first week, with a mean (SE) LDL-C reduction of -48.3% (10.4%) from baseline to week 24. ApoB (mean [SE], -41.3% [9.0%]), non-high-density lipoprotein cholesterol (-48.9% [9.8%]), and total cholesterol (-49.1% [8.1%]) were similarly decreased. Treatment-emergent adverse events were reported in 10 (71.4%) patients; however, only 2 (14.3%) reported events that were considered to be treatment-related (nausea and abdominal pain). One serious treatment-emergent adverse event of tonsillitis occurred (n=1), but this was not considered treatment-related. CONCLUSIONS: Evinacumab constitutes a new treatment for pediatric patients with HoFH and inadequately controlled LDL-C despite optimized lipid-lowering therapy, lowering LDL-C levels by nearly half in these extremely high-risk and difficult-to-treat individuals. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04233918.
Source: Circulation
Authors: Albert Wiegman, Susanne Greber-Platzer, Shazia Ali, M. Doortje Reijman, Eliot A Brinton, Min-Ji Charng, Shubha Srinivasan, Carissa Baker-Smith, Seth Baum, Julie A. Brothers, Jacob Hartz, Patrick M. Moriarty, Jeanne Mendell, Sébastien Bihorel, Poulabi Banerjee, Richard T. George, Boaz Hirshberg, Robert Pordy
Institutions: Amsterdam UMC Location University of Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Medical University of Vienna, Regeneron (United States), Shin Kong WHS Memorial Hospital, The University of Sydney, Children's Hospital at Westmead, Nemours Children's Health System, Children's Hospital of Philadelphia, Boston Children's Hospital, University of Kansas Medical Center
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Regeneron Pharmaceuticals
OpenAlex ID: W4387798656
